Suwanee, GA, April 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB:SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today commented on the Company’s promotional activities.
Over the past six weeks, SANUWAVE has released a number of press releases with material information including:
- SANUWAVE’s Letter to Stakeholders – A Look Back at 2018, a Glance Forward to 2019 and Beyond (2/19/2019)
- SANWUAVE, Proud Winner of the JWC 2019 Innovation in Chronic Wound Healing Award for dermaPACE® (3/6/2019)
- SANUWAVE Announces Plans to Attend a Total of Seven Medical and Investor Conferences in March, April and May (3/13/2019)
- SANUWAVE Reports Record 2018 Financial Results (3/29/2019)
- SANUWAVE Receives U.S. and European Patents for Intracorporeal Shockwave Systems for Treating Blood Vessels in Cardiology and Endovascular Fields (4/2/2019)
- SANWUAVE Launches Two Studies: Perfusion and Dosing; Results Expected in 2019 (4/4/2019)
SANUWAVE has been working to increase its exposure to the investment community and broaden its stockholder base since the beginning of 2019. The Company engaged various investor relations firms to support these increased outreach activities and present the SANUWAVE story. This has included an increase in social media activity on sites such as LinkedIn, Facebook and Twitter. In late March, the Company also released its own newsletter, The Pulse reaches 3,000 contacts, mainly in the healthcare field.
The Company has engaged Porter, LeVay and Rose, CNA Finance, PCG Advisory, Millennium Park Capital LLC, and Invictus Resources to provide investor relations services; compensation may include warrants to purchase the Company’s securities which has been disclosed in Form 10-Q and Form 10-K filings with the SEC. Upon inquiry of management, directors, control persons, officers and third-party service providers it has been determined that the creation, distribution or payment of any promotional materials was made directly by these engaged service providers and payments were made indirectly by the Company through the service agreements with each provider. The Company did not have editorial control over any of the editorial materials.
In early April, SANUWAVE management presented at an investor conference in New York City, and met with over 20 current and potential new investors. In addition, while performing dermaPACE system installations in various cities across the United States, SANUWAVE management also meets with additional potential new investors.
In light of the increased trading activity in the Company’s shares this past week, SANUWAVE wants to restate the Company’s position that it does not endorse any price actions or targets or claims made by independent newsletters which have used its previously released press releases as part of their outreach efforts.
The Company is aware the promotional activities began on April 22, 2019. The Company believes there was an effect on the trading activity as a result of the promotional activities. The promotional activities consisted of email promotions based on publicly available information about the Company that were paid for by our third-party service providers.
Upon inquiry of management, directors, control persons, officers and third-party service providers it has been determined that none of the parties have sold the Company’s securities within the last 90 days and two directors have exercised warrants due to expire on May 1, 2019 and purchased the Company’s securities within the last 90 days; the respective SEC Form 4 was filed on April 25, 2019.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.SANUWAVE.com.